A Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
Enrolling By Invitation
12 years - 99 years
All
Phase
2
148 participants needed
1 Location
Brief description of study
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Pancreatic Cancer,PPGL,pNET
-
Age: 12 years - 99 years
-
Gender: All
Male and Female, Age 12 and older , Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET)
Updated on
04 Aug 2024.
Study ID: 850867
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
